The demo reached both of those its Most important endpoints, with semaglutide 2.four mg demonstrating statistically significant and remarkable improvements in liver fibrosis without any worsening of steatohepatitis, and also resolution of steatohepatitis without worsening of liver fibrosis in people with MASH compared to placebo.oneParticular Popul